Novel frontiers in neuroprotective therapies in glaucoma: Molecular and clinical aspects

A Boccaccini, D Cavaterra, C Carnevale… - Molecular Aspects of …, 2023 - Elsevier
In the last years, neuroprotective therapies have attracted the researcher interests as
modern and challenging approach for the treatment of neurodegenerative diseases, aimed …

[HTML][HTML] Topical medication therapy for glaucoma and ocular hypertension

T Wang, L Cao, Q Jiang, T Zhang - Frontiers in Pharmacology, 2021 - frontiersin.org
Glaucoma is one of the most common causes of blindness, thus seriously affecting people's
health and quality of life. The topical medical therapy is as the first line treatment in the …

Preservative-free prostaglandin analogs and prostaglandin/timolol fixed combinations in the treatment of glaucoma: efficacy, safety and potential advantages

G Holló, A Katsanos, KG Boboridis, M Irkec… - Drugs, 2018 - Springer
Glaucoma therapy-related ocular surface disease (OSD) is a serious pathology with a broad
spectrum of insidious clinical presentations and complex pathogenesis that undermines …

Acetazolamide encapsulated dendritic nano-architectures for effective glaucoma management in rabbits

V Mishra, NK Jain - International journal of pharmaceutics, 2014 - Elsevier
The present investigation was aimed to develop topically effective acetazolamide loaded
poly (propylene imine) dendrimer nanoarchitectures and evaluate their intraocular pressure …

Citicoline oral solution in glaucoma: is there a role in slowing disease progression?

L Ottobelli, GL Manni, M Centofanti, M Iester… - …, 2013 - karger.com
Purpose: To assess the effect of citicoline on visual field rates of progression in patients with
progressing glaucoma. Patients and Methods: Forty-one patients with a diagnosis of …

[HTML][HTML] Morphological and functional evaluation of oral citicoline therapy in chronic open-angle glaucoma patients: a pilot study with a 2-year follow-up

M Lanza, UA Gironi Carnevale, L Mele… - Frontiers in …, 2019 - frontiersin.org
Aims: To study the neuroprotective effect of oral citicoline (CT) therapy in primary open-
angle glaucoma (POAG). Methods: This study included one eye each of 60 POAG patients …

Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers

M Iester, S Telani, P Frezzotti, I Motolese… - Journal of ocular …, 2014 - liebertpub.com
Purpose: To determine whether there were ocular surface changes in glaucomatous
patients treated with preservatives beta-blockers who switched to preservative-free beta …

Evaluating the novel application of cyclosporine 0.1% in ocular surface disease

KG Boboridis, AGP Konstas - Expert Opinion on Pharmacotherapy, 2018 - Taylor & Francis
Introduction: Ocular surface disease (OSD) is a highly prevalent symptomatic condition
caused by dry eye disease (DED), intrinsic, environmental, or iatrogenic causes. It affects …

Beta-blockers: current state of knowledge and perspectives

M Ogrodowczyk, K Dettlaff… - Mini reviews in medicinal …, 2016 - ingentaconnect.com
It has been over half a century since propranolol, the first beta-blocker, was developed for
medical treatment. Since that time a large number of compounds from this group have been …

In vivo confocal microscopy of conjunctiva in preservative‐free timolol 0.1% gel formulation therapy for glaucoma

P Frezzotti, P Fogagnolo, G Haka… - Acta …, 2014 - Wiley Online Library
Purpose To evaluate the effects at 1 year of preservative‐free timolol gel and preserved
timolol eye drops on conjunctiva and tear parameters. Methods Forty patients with primary …